Table 3 Clinical trials using immune checkpoint inhibitors in HNSCC (May 2022 clinicaltrials.org)

Target	Drug name	Indication	Combined drugs	Enrollment	Phase	Status	Clinical Trials Gov Identifier/ references
CTLA-4	Ipilimumab	Advanced HNSCC	Cetuximab, Radiation	19	Ib	Active, not recruiting	[78]
PD-1	Nivolumab	HNSCC	Cetuximab, Methotrexate, Docetaxel	361	III	Completed	[81]
	Pembrolizumab	R/M HNSCC	/	192	Ib	Completed	[83,84,85]
		HNSCC	/	172	II	Completed	[86]
		R/M HNSCC	Cisplatin, Carboplatin, 5-FU, Cetuximab	882	III	Active, not recruiting	[87]
	Cemiplimab	Advanced Cancer, Advanced Malignancies	Hypo fractionated radiotherapy, Cyclophosphamide, Docetaxel, Carboplatin, GM-CSF, Paclitaxel, Pemetrexed	398	I	Completed	[89]
		R/M HNSCC, p16-Positive OSCC	Carboplatin, Paclitaxel	33	II	Recruiting	NCT04862650
		HNSCC	REGN6569	85	I	Recruiting	NCT04465487
		OSCC	ISA101B	86	II	Recruiting	NCT04398524
		HNSCC	/	44	II	Not yet recruiting	NCT04831450
PD-L1	Atezolizumab	R/M HNSCC	/	32	I	Completed	[91]
	Durvalumab	HNSCC	/	62	I/ II	Completed	[93]
		PD-L1-positive or -Negative R/M HNSCC	Tremelimumab, SoC (cetuximab, a taxanes, methotrexate, or a fluoropyrimidine)	736	III	Completed	[94]
		Locally Advanced HNSCC	Cetuximab, Radiation	69	I/ II	Not yet recruiting	[95]
		HNSCC, M HNSCC	Radiation, Tremelimumab	45	I/ II	Active, not recruiting	[96]
	Avelumab	Locally Advanced HNSCC	Cetuximab, Cisplatin, IMRT	707	III	Active, not recruiting	[98]

ISSN: 1475-2867